Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study
Open Access
- 1 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Immunotherapy Advances
- Vol. 4 (1) , ltae001
Abstract
This phase 3, open-label, multidose study (NCT04346108) evaluated the pharmacokinetics, safety, tolerability, and efficacy of immunoglobulin subcutaneous (human) 20% solution (Ig20Gly) administered weekly and every 2 weeks in Japanese patients with primary immunodeficiency diseases (PIDs). The study was conducted at eight study sites in Japan and enrolled patients aged ≥2 years with PIDs treated using a stable intravenous immunoglobulin dose for ≥3 months prior to the study. Patients received intravenous immunoglobulin every 3 or 4 weeks at pre-study dose (200–600 mg/kg) for 13 weeks (Epoch 1), subcutaneous Ig20Gly (50–200 mg/kg) once weekly for 24 weeks (Epoch 2), and Ig20Gly (100–400 mg/kg) every 2 weeks for 12 weeks (Epoch 3). The primary endpoint was serum total immunoglobulin G (IgG) trough levels during Epochs 2 and 3. Overall, 17 patients were enrolled (median [range] age: 24 [5–69] years; 59% male) and participated in Epochs 1 and 2; seven patients entered Epoch 3. Serum total IgG trough levels were maintained at >8 g/l: geometric means (95% confidence intervals) at the end of Epochs 2 and 3 were 8.56 (8.03–9.12) g/l and 8.39 (7.89–8.91) g/l, respectively. Related treatment-emergent adverse events were all mild in severity; the most common treatment-emergent adverse events (excluding infections) in Epochs 2 and 3 were injection site swelling (24%) and injection site erythema (18%). This is the first trial to demonstrate the efficacy and favourable safety profile of 20% subcutaneous immunoglobulin administered every 2 weeks in adult and paediatric Japanese patients with PIDs.Keywords
Funding Information
- Takeda Pharmaceuticals International
This publication has 24 references indexed in Scilit:
- Practice parameter for the diagnosis and management of primary immunodeficiencyJournal of Allergy and Clinical Immunology, 2015
- Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency DiseasesJournal of Clinical Immunology, 2014
- Improved Quality of Life, Immunoglobulin G Levels, and Infection Rates in Patients with Primary Immunodeficiency Diseases during Self-Treatment with Subcutaneous Immunoglobulin GSouthern Medical Journal, 2010
- Subcutaneous immunoglobulin: opportunities and outlookClinical and Experimental Immunology, 2009
- Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectations2008
- US Valuation of the EQ-5D Health StatesMedical Care, 2005
- Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patientsThe Journal of Pediatrics, 1999
- The PedsQL™: Measurement Model for the Pediatric Quality of Life InventoryMedical Care, 1999
- The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.1992
- Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions.1991